Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
September 13 2017 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the
appointment of Kristine Peterson to its Board of Directors. Ms.
Peterson will also serve as a member of the Compensation Committee
and the Nominating and Corporate Governance Committee of Enanta’s
Board of Directors. The appointment of Ms. Peterson increases the
number of Enanta Directors to seven.
“Kristine’s broad therapeutic marketing and commercialization
experience will be invaluable as we advance our development
programs and when we evaluate any new business opportunities for
the company,” commented Jay R. Luly, Ph.D. President and Chief
Executive Officer. “I look forward to her guidance during this
period of growth for the company.”
Ms. Peterson has over 25 years of senior executive experience in
commercial and business leadership roles in the pharmaceutical and
biotechnology industry. From 2009 to 2016, Ms. Peterson served as
Chief Executive Officer of Valeritas, Inc., a commercial-stage
medical technology company where, under her leadership, the
organization evolved from a research stage company to a commercial
enterprise. Previously she held executive global marketing and
commercial roles at Johnson & Johnson from 2004 to 2009, most
recently as Company Group Chair, Biotech Sector, where she was
responsible for commercial, R&D, and biologics manufacturing
for biotech, oncology, immunology and cell therapy. From 2003 to
2004, she served as Senior Vice President, Commercial Operations
for Biovail Corporation and President of Biovail Pharmaceuticals.
Earlier in her career, she spent 20 years at Bristol-Myers Squibb
Company in senior sales and marketing roles of increasing
responsibility in a broad range of therapeutic areas that included
Cardiovascular, Metabolic, Anti-infective, Virology, Neuroscience,
Immunology/Inflammation, Pulmonary, and Oncology.
Ms. Peterson currently serves on the Boards of Directors of
Amarin Corporation plc, ImmunoGen, Inc., Paratek Pharmaceuticals,
Inc. and pSivida Corp. She received a Master of Business
Administration and a Bachelor of Science from the University of
Illinois at Urbana-Champaign.
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
paritaprevir and glecaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved in
jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the U.S. marketed regimens MAVYRET™
(glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir).
Royalties and milestone payments from the AbbVie collaboration
are helping to fund Enanta’s research and development efforts,
which are currently focused on the following disease targets:
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), respiratory syncytial virus (RSV) and hepatitis B virus
(HBV). Please visit www.enanta.com for more information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170913005121/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024